Bridgeway Capital Management, LLC Infinity Pharmaceuticals, Inc. Transaction History

Bridgeway Capital Management, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.49 - $1.2 $15,190 - $37,200	-31,000 Reduced 11.07%	249,000 $157,000
Q1 2022 May 16, 2022	BUY	$0.85 - $2.4 $119,000 - $336,000	140,000 Added 100.0%	280,000 $319,000
Q4 2021 Feb 14, 2022	SELL	$1.86 - $3.36 $489,366 - $884,016	-263,100 Reduced 65.27%	140,000 $315,000
Q3 2021 Nov 15, 2021	SELL	$1.52 - $3.82 $216,144 - $543,204	-142,200 Reduced 26.08%	403,100 $1.38 Million
Q2 2021 Aug 16, 2021	BUY	$2.66 - $3.47 $357,770 - $466,715	134,500 Added 32.74%	545,300 $1.63 Million
Q1 2021 May 17, 2021	SELL	$1.98 - $5.36 $16,830 - $45,560	-8,500 Reduced 2.03%	410,800 $1.33 Million
Q2 2020 Aug 14, 2020	BUY	$0.77 - $1.13 $7,161 - $10,508	9,300 Added 2.27%	419,300 $379,000
Q1 2020 May 15, 2020	SELL	$0.69 - $1.52 $59,960 - $132,088	-86,900 Reduced 17.49%	410,000 $343,000
Q2 2019 Aug 14, 2019	BUY	$1.43 - $1.87 $77,792 - $101,728	54,400 Added 12.29%	496,900 $894,000
Q1 2019 May 15, 2019	BUY	$1.18 - $1.91 $192,930 - $312,285	163,500 Added 58.6%	442,500 $832,000
Q4 2018 Feb 14, 2019	SELL	$1.01 - $2.78 $181,800 - $500,399	-180,000 Reduced 39.22%	279,000 $329,000
Q3 2017 Nov 14, 2017	BUY	$0.94 - $1.35 $431,460 - $619,650	459,000	459,000 $610,000

1.26M

Ticker INFI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 89,277,904
Description
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of met...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.